Value Creators: Revenio
Translation: Original report published in Finnish on 10/1/2024 at 12:15 noon EEST.
In the Value Creators concept, we highlight companies that have created substantial shareholder value. The reports do not include forecasts; they are based solely on historical data and key figures derived from it.
We evaluate companies based on the following indicators:
- Revenue development
- Operating profit development and profitability (%)
- Return on capital (%)
- Cash flow generated from operations
- Share price development and historical valuations
- Data is primarily sourced from Bloomberg
We look at the long-term development and all figures are presented with the time series 2014-2023. The reports do not constitute investment recommendations.
In this report, we introduce Revenio - a global leader in ophthalmic equipment and software solutions, with a focus on eye care solutions.
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures08.08
2023 | 24e | 25e | |
---|---|---|---|
Omsætning | 96,6 | 105,2 | 120,9 |
vækst-% | -0,45 % | 8,90 % | 14,97 % |
EBIT (adj.) | 28,5 | 28,6 | 36,9 |
EBIT-% (adj.) | 29,53 % | 27,16 % | 30,55 % |
EPS (adj.) | 0,80 | 0,83 | 1,09 |
Udbytte | 0,38 | 0,40 | 0,57 |
Udbytte % | 1,51 % | 1,47 % | 2,11 % |
P/E (adj.) | 31,50 | 32,50 | 24,69 |
EV/EBITDA | 22,03 | 21,94 | 16,92 |